The PPAR beta delta-induced mesenchymal stromal cell secretome has cytoprotective effects via ANGPTL4 in a pre-clinical model of acute lung inflammation

This study demonstrates that activating PPAR beta delta in human mesenchymal stromal cells enhances their therapeutic efficacy in a pre-clinical model of acute lung inflammation by inducing the secretion of ANGPTL4, which mediates anti-inflammatory, reparative, and cytoprotective effects.

The Gist

The Big Picture: Fixing a Broken Lung with "Smart" Cells

Imagine your lungs are a delicate, high-tech city. When a severe infection hits (like in Acute Respiratory Distress Syndrome, or ARDS), the city goes into chaos. The streets flood, the buildings (lung cells) start crumbling, and the police (immune system) are fighting so hard they accidentally damage the city further.

Doctors have been trying to send in Mesenchymal Stromal Cells (MSCs) as "repair crews" to fix this. These are special cells that can calm the immune system and help rebuild tissue. However, in the past, these repair crews often arrived and just... sat there. They didn't do much. About 60% of the time, the treatment didn't work.

Why? The researchers realized the "city" (the patient's lung environment) was too toxic for the repair crews to function properly. The air was filled with "free fatty acids" (FFAs)—think of these as toxic smog or chemical spills that confused the repair crews.

The Discovery: Turning on the "Superpower Switch"

The scientists discovered that these repair crews have a specific switch inside them called PPARβ/δ. This switch is designed to react to the toxic smog (FFAs).

• The Problem: In the past, they just sent the crews in without checking if the switch was on or off.
• The Experiment: The team decided to "prime" the crews before sending them in. They used a synthetic "key" (a drug called an agonist) to flip the PPARβ/δ switch ON.

The Result: When the switch was flipped ON, the repair crews didn't just sit there; they went into Super Repair Mode.

The Secret Weapon: ANGPTL4 (The "Glue" and "Brick Layer")

When the switch was flipped, the repair crews started pumping out a massive amount of a specific protein called ANGPTL4.

Think of ANGPTL4 as a magical construction glue and brick-layer combined.

1. The Glue: It seals the cracks in the lung's walls (the endothelial barrier), stopping the "flooding" (leakage of fluid into the lungs).
2. The Brick Layer: It tells the damaged lung cells to grow back faster and move to the broken spots to fix the holes.

The researchers proved this by taking the "Super Repair" fluid from the activated cells and removing the ANGPTL4 glue. Without the glue, the repair stopped. This confirmed that ANGPTL4 was the star of the show.

The "Double-Boost" Strategy: Training with the Enemy

Here is where it gets really clever. The researchers knew that the toxic smog (FFAs) in ARDS patients was strong. So, they tried a new training method:

1. Step 1: They exposed the repair cells to the PPARβ/δ switch activator (the key).
2. Step 2: They then exposed those cells to actual blood serum from ARDS patients (the toxic environment).

The Analogy: Imagine training a firefighter. First, you give them a special suit (the drug). Then, you throw them into a controlled fire (the patient's blood) to practice.

The Outcome: This "double-boost" made the cells produce 10 times more ANGPTL4 than just using the drug alone. It was like the cells realized, "Oh, we are in a real emergency! We need to bring out the heavy-duty glue!"

What Happened in the Mouse Test?

The team tested this on mice with inflamed lungs.

• The Control Group: Mice got regular repair cells. The lungs were still leaky and inflamed.
• The "Double-Boost" Group: Mice got the super-charged, ARDS-trained cells.
  • The Leaks Stopped: The lungs held their shape better; the "flooding" was reduced.
  • The Fire Doused: The inflammation (TNF and IL-6) went down significantly.
  • The Weight: The mice didn't lose as much weight (a sign of being sick).

The Takeaway

This paper tells us that MSCs are not one-size-fits-all. They are like smart robots that can be programmed.

1. The environment of a sick lung (full of fatty acids) actually has the potential to help the repair cells if we know how to use it.
2. By flipping a specific internal switch (PPARβ/δ) and letting the cells "practice" in the patient's own blood, we can turn them into super-repair crews.
3. The secret weapon they produce is ANGPTL4, which acts as the ultimate glue to seal and rebuild damaged lungs.

In short: Instead of just sending in a generic repair crew, the scientists learned how to "license" them with the specific tools they need to survive the toxic environment of a sick lung, turning them into a highly effective treatment for lung failure.

Technical Summary

1. Problem Statement

Mesenchymal stromal cells (MSCs) are promising therapeutic candidates for inflammatory diseases like Acute Respiratory Distress Syndrome (ARDS) due to their immunomodulatory and pro-reparative capacities. However, clinical trials have shown poor outcomes (~60% non-responders), likely because the complex ARDS microenvironment alters MSC functionality.

• The Gap: The ARDS microenvironment is rich in free fatty acids (FFAs), which are natural ligands for the nuclear receptor PPARβ/δ. While PPARβ/δ modulation has been studied in mouse MSCs, its impact on human MSCs (hBM-MSCs) and the specific molecular mechanisms driving therapeutic efficacy in an ARDS context remain poorly understood.
• The Objective: To investigate how PPARβ/δ modulation (agonism vs. antagonism) affects the hBM-MSC secretome, specifically focusing on immunomodulation and tissue repair, and to determine if "licensing" MSCs with ARDS patient serum enhances these effects.

2. Methodology

The study employed a multi-faceted approach combining in vitro assays, omics analysis, and a pre-clinical in vivo model.

• Cell Culture & Conditioning:
  • Human bone marrow-derived MSCs (hBM-MSCs) were treated with a synthetic PPARβ/δ agonist (GW0742) or antagonist (GSK3787).
  • Cells were also exposed to ARDS patient serum (derived from SARS-CoV-2 patients) to mimic the in vivo microenvironment.
  • Conditioned Media (MSC-CM) was harvested to test the secretome's effects.
• In Vitro Assays:
  • Scratch Assay: Used on CALU-3 lung epithelial cells to measure wound healing (migration/proliferation). Mitomycin C was used to distinguish between proliferation and migration.
  • Neutralization: Anti-ANGPTL4 antibodies were used to block specific factors in the secretome to confirm mechanisms.
  • Gene/Protein Analysis: RT-qPCR and ELISA were used to quantify expression of factors like ANGPTL4, VEGF, and cytokines.
• Omics Analysis:
  • RNA Sequencing: Performed on MSCs treated with agonist/antagonist to identify Differentially Expressed Genes (DEGs).
  • Public Data Mining: Utilized existing metabolomics and RNA-seq datasets (GEO: GSE185263, ST000042) to analyze FFA levels and PPARβ/δ co-regulators in ARDS patients.
• In Vivo Model (ALI):
  • Model: LPS-induced Acute Lung Injury (ALI) in C57BL6/J mice.
  • Intervention: Intranasal administration of concentrated MSC-CM (equivalent to a low dose of $5 \times 10^4$ cells) 4 hours post-LPS challenge.
  • Readouts: Lung permeability (Evans Blue dye), BALF cytokine levels (TNF-α, IL-6, IL-1β), clinical scoring, weight loss, and ANGPTL4 neutralization effects.

3. Key Contributions

1. Identification of ANGPTL4 as a Key Mediator: The study identifies Angiopoietin-like protein 4 (ANGPTL4) as the primary cytoprotective factor upregulated in hBM-MSCs upon PPARβ/δ agonism.
2. Mechanism of Action: Demonstrates that PPARβ/δ activation enhances MSC-mediated lung epithelial repair and vascular barrier integrity specifically through an ANGPTL4-dependent pathway.
3. "Licensing" Strategy: Proves that pre-conditioning ("licensing") MSCs with ARDS patient serum combined with PPARβ/δ agonism creates a super-charged secretome with significantly enhanced therapeutic efficacy compared to either treatment alone.
4. Human Relevance: Unlike many studies relying on mouse MSCs, this work focuses on human BM-MSCs, addressing a critical gap in translational research.

4. Key Results

• In Vitro Repair:
  • MSC-CM from PPARβ/δ-agonized cells (MSC-CM$^{PPAR\beta/\delta(+)}$) significantly enhanced wound closure in CALU-3 cells compared to naive or antagonist-treated cells.
  • This effect was driven by both migration and proliferation (confirmed via Mitomycin C and TOP2A gene expression).
  • Neutralization: Blocking ANGPTL4 with a neutralizing antibody completely abrogated the enhanced wound healing, confirming ANGPTL4 is the critical effector.
• Transcriptomic & Metabolomic Findings:
  • RNA-seq revealed significant upregulation of ANGPTL4, PLIN2, and CPT1A (lipid metabolism genes) in agonized MSCs.
  • Public data analysis confirmed that ARDS patients have elevated levels of PPARβ/δ ligands (linoleate, palmitoleic acid) and co-activators (NCOA1, NCOA3), suggesting the ARDS environment naturally primes MSCs for this pathway.
• In Vivo Therapeutic Effects (ALI Model):
  • Low-Dose Efficacy: A low dose of MSC-CM alone was ineffective, but MSC-CM$^{PPAR\beta/\delta(+)}$ significantly improved vascular and epithelial barrier function (reduced Evans Blue leakage).
  • Synergistic Licensing: The combination of ARDS serum + PPARβ/δ agonist induced a 10-fold increase in ANGPTL4 secretion.
  • Clinical Outcomes: The "ARDS-licensed" MSC-CM$^{PPAR\beta/\delta(+)}$ significantly reduced:
    • Pro-inflammatory cytokines (TNF-α, IL-6) in BALF.
    • Weight loss in mice.
    • Clinical scores (trend toward significance).
  • Validation: The therapeutic benefits of the licensed secretome were reversed when ANGPTL4 was neutralized, confirming the mechanism in vivo.

5. Significance and Conclusion

This study provides a novel strategy to overcome the limitations of current MSC therapies for ARDS.

• Mechanistic Insight: It clarifies that the ARDS microenvironment (rich in FFAs) activates PPARβ/δ in human MSCs, triggering a reparative secretome dominated by ANGPTL4.
• Therapeutic Optimization: The authors propose a "licensing" protocol where MSCs are pre-treated with PPARβ/δ agonists and ARDS patient serum to maximize the production of ANGPTL4.
• Clinical Implication: This approach transforms a sub-therapeutic dose of MSCs into a potent therapy capable of restoring lung barrier integrity and reducing inflammation. It suggests that future clinical trials should consider "priming" or "licensing" MSCs to match the specific metabolic and inflammatory profile of the patient's disease state, rather than administering naive cells.

Limitations Noted: The in vivo study used a small sample size ($n=3$) for the combined licensing group due to limited availability of ARDS patient serum, and the study did not detect significant effects from PPARβ/δ antagonism in human MSCs, contrasting with some previous mouse studies.